KEZAR LIFE SCIENCES INC (KZR)
US49372L1008 - Common Stock
We assign a fundamental rating of 2 out of 10 to KZR. KZR was compared to 588 industry peers in the Biotechnology industry. While KZR seems to be doing ok healthwise, there are quite some concerns on its profitability. KZR is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year KZR has reported negative net income.
KZR had a negative operating cash flow in the past year.
KZR had negative earnings in each of the past 5 years.
KZR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -46.05%, KZR is in line with its industry, outperforming 53.24% of the companies in the same industry.
Looking at the Return On Equity, with a value of -54.31%, KZR is in the better half of the industry, outperforming 65.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.05% | ||
| ROE | -54.31% | ||
| ROIC | N/A |
ROA(3y)-31.3%
ROA(5y)-32.12%
ROE(3y)-35.78%
ROE(5y)-36.39%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KZR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KZR does not have a ROIC to compare to the WACC, probably because it is not profitable.
KZR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, KZR has more shares outstanding
KZR has a worse debt/assets ratio than last year.
2.2 Solvency
KZR has an Altman-Z score of -1.62. This is a bad value and indicates that KZR is not financially healthy and even has some risk of bankruptcy.
KZR has a Altman-Z score (-1.62) which is comparable to the rest of the industry.
KZR has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, KZR is doing worse than 60.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.62 |
ROIC/WACCN/A
WACC9.39%
2.3 Liquidity
KZR has a Current Ratio of 11.66. This indicates that KZR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of KZR (11.66) is better than 83.11% of its industry peers.
KZR has a Quick Ratio of 11.66. This indicates that KZR is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 11.66, KZR belongs to the best of the industry, outperforming 83.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.66 | ||
| Quick Ratio | 11.66 |
3. Growth
3.1 Past
KZR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.60%.
EPS 1Y (TTM)-39.6%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, KZR will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.66% on average per year.
The Revenue is expected to grow by 63.57% on average over the next years. This is a very strong growth
EPS Next Y3.13%
EPS Next 2Y4.97%
EPS Next 3Y3.61%
EPS Next 5Y10.66%
Revenue Next Year-58.33%
Revenue Next 2Y-22.84%
Revenue Next 3Y-25.99%
Revenue Next 5Y63.57%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KZR. In the last year negative earnings were reported.
Also next year KZR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.97%
EPS Next 3Y3.61%
5. Dividend
5.1 Amount
No dividends for KZR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KEZAR LIFE SCIENCES INC
NASDAQ:KZR (5/3/2024, 7:02:43 PM)
After market: 0.833 -0.02 (-2.85%)0.8574
+0 (+0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap62.42M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.05% | ||
| ROE | -54.31% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 11.66 | ||
| Quick Ratio | 11.66 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-39.6%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y3.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y